Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finotonlimab + Neoadjuvant Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma
NCT07248956Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of finotonlimab in hypopharyngeal carcinoma (HPC), sponsored by Eye and ENT Hospital of Fudan University. Started Dec 2025; status: recruiting.
02
Drugs
finotonlimab
03
Conditions
hypopharyngeal carcinoma (HPC)
Beyond the preview
Go deeper on NCT07248956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07248956.